GlobeNewswire: Amicus Therapeutics, Inc. Contains the last 10 of 418 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:43:24ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/20/2849230/0/en/Amicus-Therapeutics-Issues-2024-Environmental-Social-and-Governance-ESG-Report.html?f=22&fvtc=4&fvtv=12828Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report2024-03-20T11:00:00Z<![CDATA[PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report. This year’s report highlights the strength of the Company’s corporate responsibility structure including increased efforts towards transparency in our environmental reporting, our deep commitment to ensuring broad and equitable access to our innovative therapies, fostering an inclusive culture to ensure equal representation and participation for all, and maintaining our leadership of strong business ethics and integrity.]]>https://www.globenewswire.com/news-release/2024/03/01/2838732/0/en/Amicus-Therapeutics-to-Present-at-Upcoming-Investor-Conferences-in-March-2024.html?f=22&fvtc=4&fvtv=12828Amicus Therapeutics to Present at Upcoming Investor Conferences in March 20242024-03-01T12:00:00Z<![CDATA[PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.]]>https://www.globenewswire.com/news-release/2024/02/28/2836812/0/en/Amicus-Therapeutics-Announces-Full-Year-2023-Financial-Results-and-Corporate-Updates.html?f=22&fvtc=4&fvtv=12828Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates2024-02-28T12:00:00Z<![CDATA[2023 Total Revenue of $399.4M, a 21% Increase Year-over-Year]]>https://www.globenewswire.com/news-release/2024/02/15/2829804/0/en/Amicus-Therapeutics-to-Announce-Full-Year-2023-Financial-Results-on-February-28-2024.html?f=22&fvtc=4&fvtv=12828Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 20242024-02-15T12:00:00Z<![CDATA[PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 2024, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/02/08/2825867/0/en/Amicus-Therapeutics-Receives-the-2024-New-Treatment-Award-for-Pombiliti-cipaglucosidase-alfa-atga-Opfolda-miglustat-at-the-20th-Annual-WORLDSymposium.html?f=22&fvtc=4&fvtv=12828Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™2024-02-08T12:00:00Z<![CDATA[- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease - - Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease -]]>https://www.globenewswire.com/news-release/2024/02/01/2821842/0/en/Amicus-Therapeutics-Announces-Presentations-and-Posters-at-the-20th-Annual-WORLDSymposium-2024.html?f=22&fvtc=4&fvtv=12828Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 20242024-02-01T12:00:00Z<![CDATA[PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11 posters across its development programs will be included at the 20th Annual WORLDSymposium™ 2024, being held February 4-9, 2024 in San Diego, CA.]]>https://www.globenewswire.com/news-release/2024/01/07/2805020/0/en/Amicus-Therapeutics-Reports-Preliminary-2023-Revenue-and-Provides-2024-Strategic-Outlook.html?f=22&fvtc=4&fvtv=12828Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook2024-01-07T21:00:52Z<![CDATA[2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year]]>https://www.globenewswire.com/news-release/2024/01/03/2803153/0/en/Amicus-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=12828Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference2024-01-03T12:00:00Z<![CDATA[PRINCETON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 8, 2024, at 2:15 p.m. PT.]]>https://www.globenewswire.com/news-release/2023/12/05/2790725/0/en/Amicus-Therapeutics-Congratulates-Executive-Chairman-John-F-Crowley-on-Appointment-as-Next-President-and-CEO-of-BIO.html?f=22&fvtc=4&fvtv=12828Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO2023-12-05T11:00:38Z<![CDATA[Crowley to Step Down from Amicus Board of Directors in March 2024 and Become Amicus Chairman Emeritus]]>https://www.globenewswire.com/news-release/2023/11/08/2776065/0/en/Amicus-Therapeutics-Announces-Third-Quarter-2023-Financial-Results-and-Corporate-Updates.html?f=22&fvtc=4&fvtv=12828Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates2023-11-08T12:00:00Z<![CDATA[3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER]]>